Oncology Marketing Lead — Netherlands Launch & Omnichannel

Revolution Medicines, Inc.; Nederland; On-site; EUR 120,000 - 180,000; Full time

Job summary

Revolution Medicines in the Netherlands is seeking an Associate Director Marketing to lead the oncology portfolio's launch, branding and omnichannel strategy. You will coordinate across Marketing, Field Force, Medical Affairs, Market Access and Operations to translate global plans into locally relevant execution.

The role requires close collaboration with European teams, ensuring market-driven, data-informed initiatives and a customer-centric approach to accelerate portfolio performance in the

Responsibilities

• Product Launch & Commercial Readiness Leadership for NL launches.
• Translate European strategies into locally relevant launch plans based on market insights.
• Orchestrate cross-functional launch readiness across Marketing, Field Force, Strategic Planning & Operations, Medical Affairs, Market Access.
• Develop and ensure compliant promotional materials and sales campaigns for the Netherlands.
• Define the optimal promotional mix to support launch and portfolio establishment in NL.
• Provide strategic direction for the product and brand portfolio, linking brand, product and customer engagement strategies.
• Lead omnichannel and customer experience across the Oncology portfolio in collaboration with the European team.
• Align with Field Force and European strategy to ensure consistent execution in the Dutch market.

Skills

Strategic marketing leadership

Omnichannel marketing

Cross-functional collaboration

Job description

Revolution Medicines in the Netherlands is seeking an Associate Director Marketing to lead the oncology portfolio's launch, branding and omnichannel strategy. You will coordinate across Marketing, Field Force, Medical Affairs, Market Access and Operations to translate global plans into locally relevant execution.

The role requires close collaboration with European teams, ensuring market-driven, data-informed initiatives and a customer-centric approach to accelerate portfolio performance in the